You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 4,588,585

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 4,588,585

Title:	Human recombinant cysteine depleted interferon-.beta. muteins
Abstract:	Muteins of biologically active proteins such as IFN-.beta. and IL-2 in which cysteine residues that are not essential to biological activity have been deleted or replaced with other amino acids to eliminate sites for intermolecular crosslinking or incorrect intramolecular disulfide bridge formation. These muteins are made via bacterial expression of mutant genes that encode the muteins that have been synthesized from the genes for the parent proteins by oligonucleotide-directed mutagenesis.
Inventor(s):	Mark; David F. (Danville, CA), Lin; Leo S. (Fremont, CA), Yu Lu; Shi-Da (Oakland, CA)
Assignee:	Cetus Corporation (Emeryville, CA)
Application Number:	06/655,897
Patent Claims:	1. Recombinant, synthetic human interferon-.beta. mutein, wherein the cysteine at position 17, numbered in accordance with native interferon-.beta., is deleted or replaced by a neutral amino acid, and wherein said mutein exhibits biological activity of native, human interferon-.beta.. 2. The synthetic mutein of claim 1 wherein said cysteine residue is replaced by an amino acid selected from the group consisting of serine, threonine, glycine, alanine, valine, leucine, isoleucine, histidine, tyrosine, phenylalanine, tryptophan or methionine. 3. The synthetic mutein of claim 1 wherein said cysteine residue has been replaced by an amino acid selected from the group consisting of serine or threonine. 4. The synthetic mutein of claim 1 wherein the mutein is unglycosylated. 5. Biologically active IFN-.beta..sub.ser17. 6. IFN-.beta..sub.ser17 as represented by the amino acid sequence represented in FIG. 10. 7. A therapeutic compsition having IFN-.beta. activity comprising a therapeutically effective amount of the synthetic mutein of claims 1, 2, 3, 4, 5, or 6 admixed with a pharmaceutically acceptable carrier medium. 8. A method of regulating cell growth in a patient comprising administering to said patient a cell growth regulating amount of the synthetic mutein of claims 1, 2, 3, 4, 5, or 6. 9. A method of treating a patient for viral disease comprising administering to said patient a viral disease inhibiting amount of the synthetic mutein of claims 1, 2, 3, 4, 5, or 6. 10. A method of stimulating natural killer cell activity in a patient comprising administering to said patient a natural killer cell stimulating amount of the synthetic mutein of claims 1, 2, 3, 4, 5, or 6.

Details for Patent 4,588,585

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bayer Healthcare Pharmaceuticals Inc.	BETASERON	interferon beta-1b	For Injection	103471	07/23/1993	⤷ Try a Trial	2003-05-13
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 4,588,585

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration
Austria	33503	⤷ Try a Trial
Austria	46539	⤷ Try a Trial
Austria	61407	⤷ Try a Trial
Austria	73493	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.